文献速递白血病

Interfant-06方案治疗1岁以下婴儿急性淋巴细胞白血病:国际III期随机研究结果

Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.
PubMed 文献 · J Clin Oncol · 2019-07-08

Interfant-06研究纳入651例婴儿急性淋巴细胞白血病(ALL),随机比较髓系方案(ADE+MAE)与淋系方案(IB)巩固化疗,并评估干细胞移植及预后因素。6年无事件生存(EFS)与总生存分别为46.1%和58.2%;结论:髓系方案未显著改善结局,且总体结局未优于Interfant-99。

要点

  • 婴儿ALL中KMT2A重排是最强预后因素,其次为年龄、WBC计数和泼尼松反应。
  • 中危和高危组随机接受髓系方案ADE+MAE或淋系方案IB,6年无病生存无显著差异。
  • 高危组意向移植者6年EFS为20.9%,仅46%实际接受移植,多因早期事件。

核心结论

  • 诱导后早期强化采用髓系类型化疗方案(ADE+MAE)与淋系方案IB相比,未显著改善婴儿ALL结局。
  • Interfant-06研究中婴儿ALL的结局与Interfant-99相比未改善。

研究设计与样本

  • 国际III期随机研究,由18个国家及国际研究组参与,共纳入651例婴儿。
  • 按风险分为低危(KMT2A胚系)、中危(其他KMT2A重排)和高危(KMT2A重排且年龄>6个月并WBC≥300×10⁹/L或泼尼松反应差)。
  • 中危和高危患者随机接受淋系方案IB(低剂量阿糖胞苷、6-巯基嘌呤、环磷酰胺)或实验性髓系方案ADE(阿糖胞苷、柔红霉素、依托泊苷)和MAE(米托蒽醌、阿糖胞苷、依托泊苷)。

主要发现

  • 651例婴儿6年EFS为46.1%(SE 2.1),总生存为58.2%(SE 2.0)。
  • 西欧/北美组6年EFS为49.4%(SE 2.5),总生存为62.1%(SE 2.4),比其他国家的相应率高10%至12%。
  • 高危组意向移植者6年EFS为20.9%(SE 3.4);仅46%接受了干细胞移植,因许多患者发生早期事件。
  • KMT2A重排是EFS最强预后因素,其次为年龄、WBC计数和泼尼松反应。

关键数值与推荐

  • 低危定义:KMT2A胚系。
  • 高危定义:KMT2A重排且年龄>6个月并WBC≥300×10⁹/L或泼尼松反应差。
  • 中危定义:其他KMT2A重排病例。

临床怎么用

  • 婴儿ALL可按KMT2A重排状态、年龄、WBC计数和泼尼松反应进行风险分层。
  • 诱导后采用髓系类型方案ADE+MAE与淋系方案IB相比,未显著改善结局。
  • 高危组意向移植者中仅46%实际接受移植,多因早期事件。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Infant acute lymphoblastic leukemia (ALL) is characterized by KMT2A (MLL) gene rearrangements and coexpression of myeloid markers. The Interfant-06 study, comprising 18 national and international study groups, tested whether myeloid-style consolidation chemotherapy is superior to lymphoid style, the role of stem-cell transplantation (SCT), and which factors had independent prognostic value. MATERIALS AND METHODS: Three risk groups were defined: low risk (LR): KMT2A germline; high risk (HR): KMT2A-rearranged and older than 6 months with WBC count 300 × 109/L or more or a poor prednisone response; and medium risk (MR): all other KMT2A-rearranged cases. Patients in the MR and HR groups were randomly assigned to receive the lymphoid course low-dose cytosine arabinoside [araC], 6-mercaptopurine, cyclophosphamide (IB) or experimental myeloid courses, namely araC, daunorubicin, etoposide (ADE) and mitoxantrone, araC, etoposide (MAE). RESULTS: A total of 651 infants were included, with 6-year event-free survival (EFS) and overall survival of 46.1% (SE, 2.1) and 58.2% (SE, 2.0). In West European/North American groups, 6-year EFS and overall survival were 49.4% (SE, 2.5) and 62.1% (SE, 2.4), which were 10% to 12% higher than in other countries. The 6-year probability of disease-free survival was comparable for the randomized arms (ADE+MAE 39.3% [SE 4.0; n = 169] v IB 36.8% [SE, 3.9; n = 161]; log-rank P = .47). The 6-year EFS rate of patients in the HR group was 20.9% (SE, 3.4) with the intention to undergo SCT; only 46% of them received SCT, because many had early events. KMT2A rearrangement was the strongest prognostic factor for EFS, followed by age, WBC count, and prednisone response. CONCLUSION: Early intensification with postinduction myeloid-type chemotherapy courses did not significantly improve outcome for infant ALL compared with the lymphoid-type course IB. Outcome for infant ALL in Interfant-06 did not improve compared with that in Interfant-99.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pieters R, De Lorenzo P, Ancliffe P, et al. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol. 2019. PMID: 31283407. doi:10.1200/JCO.19.00261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。